Coronavirus: Zydus Cadila launches India’s cheapest remdesivir version at Rs 2,800 per vial

First Published 13, Aug 2020, 11:33 AM

 Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd
 

<p>Zydus Cadila on Thursday (August 13) launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation.<br />
&nbsp;</p>

Zydus Cadila on Thursday (August 13) launched the cheapest generic version of Gilead Sciences' antiviral drug remdesivir in India to treat COVID-19 following reports of shortages at hospitals in the world's third-worst hit nation.
 

<p>Zydus has priced it at Rs 2,800 ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing.<br />
&nbsp;</p>

Zydus has priced it at Rs 2,800 ($37.44) per 100mg vial. It will be sold under the brand name Remdac to government and private hospitals treating COVID-19 patients, the company said in a regulatory filing.
 

<p>Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla Ltd had earlier this week said the supplies were stabilising.<br />
&nbsp;</p>

Officials in some Indian states had a few weeks ago complained of supply issues, but a top executive at drugmaker Cipla Ltd had earlier this week said the supplies were stabilising.
 

<p>Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd.<br />
&nbsp;</p>

Zydus is the fifth company to launch a copy of the antiviral in India after privately held Hetero Labs Ltd, Cipla, Mylan NV and Jubilant Life Sciences Ltd.
 

<p>Gilead has also entered into licensing agreements with Dr Reddy's Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India.</p>

Gilead has also entered into licensing agreements with Dr Reddy's Laboratories Ltd and Syngene International Ltd to make remdesivir for distribution in 127 countries, including India.

loader